Encouraging efficacy data with anti-PD1 antibody in combination or as monotherapy

Thanks to remarkable advances, molecular analysis has taken central stage in the management of GIST, but there is still a need for less costly testing and further development of mitigation strategies to overcome resistance

The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration 

Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines  

Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region 

Phase III data highlight the consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer patients, with greatest benefit in high PD-L1-expressing tumours

Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer

Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials

Immune chemo-sensitisation results show potential for this approach in the treatment of advanced CRC, but greater understanding of response characteristics is required in future clinical trials

Genomic landscaping suggests molecular divergence between cancer subtypes and across disease stages, but molecular similarities between White and Asian populations